Trial Profile
A Phase I, Open-Label, Randomized, Single Dose, Five Period, Crossover, Single Center Trial To Assess The Relative Bioavailability Of The 150 mg ODT Formulation Of L PZQ (MSC2499550A) Versus The Current 500 mg PZQ Commercial Racemate Tablet Formulation In Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2018
Price :
$35
*
At a glance
- Drugs Praziquantel (Primary)
- Indications Schistosomiasis
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 20 Jan 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 New trial record